Aerie Pharmaceuticals Inc
NASDAQ:AERI
Aerie Pharmaceuticals Inc
Revenue
Aerie Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Aerie Pharmaceuticals Inc
NASDAQ:AERI
|
Revenue
$213.9m
|
CAGR 3-Years
53%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$81.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$58.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$61.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$34.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
Aerie Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
Aerie Pharmaceuticals Inc
Breakdown by Segments
Aerie Pharmaceuticals Inc
Total Revenue:
194.1m
USD
|
Product Revenues, Net:
112.1m
USD
|
Licensing Revenues:
82m
USD
|
See Also
What is Aerie Pharmaceuticals Inc's Revenue?
Revenue
213.9m
USD
Based on the financial report for Sep 30, 2022, Aerie Pharmaceuticals Inc's Revenue amounts to 213.9m USD.
What is Aerie Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 3Y
53%
Over the last year, the Revenue growth was 105%. The average annual Revenue growth rates for Aerie Pharmaceuticals Inc have been 53% over the past three years .